Amgen Cops To Aranesp Misbranding, Will Pay $762M
Amgen Inc. pled guilty in New York federal court Tuesday to misbranding its Aranesp anemia drug and agreed to a combined $762 million civil and criminal payout to resolve long-running allegations...To view the full article, register now.
Already a subscriber? Click here to view full article